OncoMatch/Clinical Trials/NCT03897543
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Is NCT03897543 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies ABX196 for carcinoma, hepatocellular.
Treatment: ABX196 — Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — HCC
Patients with at least one prior systemic therapy for HCC
Cannot have received: tyrosine kinase inhibitor
Patients with tyrosine kinase inhibitor treatment within 2 weeks of first study dose
Cannot have received: locoregional therapy
Patients with previous locoregional therapy or major surgery to the liver within 6 weeks before first study dose
Cannot have received: surgery
Patients with minor surgery to liver or another site within 1 week before first study dose
Lab requirements
Liver function
Child-Pugh class A liver score within 7 days of first study dose; no history of hepatic encephalopathy; no prior or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control (patients with ascites only on radiographic imaging are eligible)
Child-Pugh class A liver score within 7 days of first study dose; no history of hepatic encephalopathy; no prior or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Scripps Clinic Torrey Pines · La Jolla, California
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify